home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605a.zip
/
M9650418.TXT
< prev
next >
Wrap
Text File
|
1996-03-09
|
3KB
|
51 lines
Document 0418
DOCN M9650418
TI Biological and biochemical anti-human immunodeficiency virus activity of
UC 38, a new non-nucleoside reverse transcriptase inhibitor.
DT 9605
AU McMahon JB; Buckheit RW Jr; Gulakowski RJ; Currens MJ; Vistica DT;
Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz
RJ; Brouwer WG; Felauer EE; Boyd MR; Laboratory of Drug Discovery
Research and Development, National; Cancer Institute, Frederick,
Maryland, USA.
SO J Pharmacol Exp Ther. 1996 Jan;276(1):298-305. Unique Identifier :
AIDSLINE MED/96135081
AB UC 38, a simple analog of oxathiin carboxanilide, UC 84, lacking the
oxathiin ring, was found to be a potent inhibitor of human
immunodeficiency virus (HIV)-1-induced cell killing and HIV replication
in a variety of human cell lines, as well as in human peripheral blood
lymphocytes and macrophages. UC 38 was active against a wide range of
biologically diverse laboratory and clinical strains of HIV-1. However,
UC 38 was inactive against HIV-2 and both nevirapine- and
pyridinone-resistant strains of HIV-1. UC 38 selectively inhibited HIV-1
reverse transcriptase (RT), but not HIV-2 RT. Combination of UC 38 with
3'-azido-3'-deoxythymidine synergistically inhibited HIV-induced cell
killing. An HIV-1 isolate resistant to UC 38 was selected in cell
culture, and the mutations in the RT nucleotide sequences were
determined. Comparison with the wild-type RT sequence revealed an amino
acid change at position 181 (Tyr to Cys). The UC 38-resistant virus was
found to be cross-resistant to a variety of structurally diverse
non-nucleoside RT inhibitors. UC 38 was susceptible to rapid degradation
in vitro and in vivo; yet, nontoxic in vivo concentrations of UC 38
many-fold in excess of the in vitro effective concentrations could be
achieved and maintained after s.c. or p.o. administration in hamsters.
These results establish UC 38 as a new chemotype within the general
class of HIV-1-specific RT inhibitors. The favorable physical
characteristics, lack of toxicity, potency and bioavailability of UC 38
may make it a candidate for combination chemotherapy of acquired immune
deficiency syndrome.
DE Animal Antiviral Agents/*PHARMACOLOGY/PHARMACOKINETICS
Benzoates/*PHARMACOLOGY/PHARMACOKINETICS Biological Availability
Carboxin/ANALOGS & DERIVATIVES/PHARMACOLOGY/PHARMACOKINETICS
Comparative Study Drug Administration Schedule Drug Resistance,
Microbial Drug Stability Drug Synergism DNA Mutational Analysis DNA,
Viral/ANALYSIS/GENETICS Hamsters Human HIV-1/*DRUG EFFECTS/ENZYMOLOGY
Male Mice Microbial Sensitivity Tests Rats Reverse Transcriptase
Inhibitors/*PHARMACOLOGY/PHARMACOKINETICS RNA-Directed DNA
Polymerase/*DRUG EFFECTS Thiocarbamates/*PHARMACOLOGY/PHARMACOKINETICS
Zidovudine/PHARMACOLOGY JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).